Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
JP Morgan 2019 day three roundup – Abbvie rekindles the takeover flame
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Asco 2018 event analyser – A year of reset expectations
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
Asco 2018 – German Merck’s run at US Merck and other updates
Immuno-oncology is one area where Merck & Co could see a challenge from its historic parent company.
Another huge quarter for biotech flotations
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.
